Will Savara stock go up?

According to Danelfin AI, Savara has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.90%) is +3.08% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Savara stock?

The Savara target price is $11.27 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Savara stock right now?

Savara has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (53.90%) is +3.08% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Savara stock is a good buy .

Is Savara undervalued right now?

Based on analysts, the average price target upside for Savara is +85.42% (1Y). According to Danelfin AI, Savara has today an AI Score of 5/10 (Hold Rating).

What was the price range of Savara stock over the past 12 months?

The Savara stock price range over the past 12 months has been $2.05 - $6.94.

What is going on with Savara stock in the last 3 months?

The Savara stock performance in the last quarter has been +11.35%.

Does Savara offer dividend payments?

No, Savara does not currently pay dividends.

What is the current market capitalization of Savara?

Savara's market cap is $1.24B, as of 2026-07-02 08:00.

When is the next SVRA earnings report date?

SVRA will publish its next earnings report on 2026-05-12.

Savara Inc (SVRA) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

SVRA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Savara Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 54% probability of outperforming the market in the next 3 months, which is 3% higher than the average probability of any stock (51%). Key positive contributors include the aggregated fundamentals long-tail impact (+3.45%), operating cash flow (quarterly discrete) despite being in the bottom 10% (+1.24%), and the Biotechnology industry (+0.85%). On the negative side, the 180-day chart pattern (-0.77%), the Fear & Greed Index at 31 (-0.75%), and the 504-day chart pattern (-0.65%) are the top detractors. Notable data points include a top 10% ranking for Alpha 1Y (risk-adjusted return over the past year), which positively influences the probability, while the analyst lowest price upside is in the bottom 30% and detracts. The stock's year-to-date performance is in the top 50% but still has a negative impact. Overall, the stock shows a mix of positive fundamentals and sentiment signals weighed down by technical patterns and market fear, resulting in a balanced HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+3.36%
How the stock is priced relative to its fundamentals
Earnings Quality+1.26%
Stability and reliability of reported earnings
Sentiment+0.62%
How analysts and the market view the stock
Size & Liquidity+0.22%
Company size and trading liquidity

Momentum-2.38%
Direction and strength of recent price movements

SVRA probability advantage of beating the market (3M):

+3.08%

AI Score

Hold

Savara (SVRA) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +3.08% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of SVRA (53.90%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
SVRA probability advantage of beating the market (3M)+3.08%
SVRA probability of beating the market (3M)53.90%

SVRA probability advantage of beating the market (3M): +3.08%

The AI-powered overall analysis of Savara (SVRA) is based on the 26 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of SVRA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+3.45%
Fundamental	Operating Cash Flow (Qtr Discrete)	-33.05	N/A	+1.24%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.85%
Technical	Chart Pattern (180d)	figure_187	N/A	-0.77%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.75%
Technical	Chart Pattern (504d)	figure_36	N/A	-0.65%
Fundamental	Tangible Shareholders' Equity	176.04		+0.47%
Sentiment	Analyst Lowest Price Upside	-0.34%		-0.47%
Sentiment	Earnings Countdown	-45		+0.32%
Fundamental	Cash per Share (MRQ)	0.99		-0.31%
Sentiment	Upgrade to unlock			+0.26%
Sentiment	Upgrade to unlock			+0.25%
Fundamental	Upgrade to unlock			-0.25%
Technical	Upgrade to unlock			-0.23%
Fundamental	Upgrade to unlock			+0.22%

Rest of Alpha Signals: -0.55%

SVRA probability advantage of beating the market (3M)Total:+3.08%
SVRA AI Score

Significant changes Vs previous day

SVRA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$6.08
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

SVRA Proven Hold Signal & Price Forecast

This is the price chart for SVRA from January 1, 2026 until today. The chart indicates, in yellow, the 78 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

SVRA Average Past Performance & Win Rate

Three months after its 1463 Hold signals since July 2026, SVRA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1463 Past SVRA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+14.16%
Average Alpha				+0.38%
Win Rate (% Positive Perf.)				45.72%
% Positive Alpha				42.34%

SVRA Frequently Asked Questions

Will Savara stock go up?
According to Danelfin AI, Savara has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.90%) is +3.08% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Savara stock?
Is it a good time to buy, sell, or hold Savara stock right now?
Is Savara undervalued right now?
What was the price range of Savara stock over the past 12 months?
What is going on with Savara stock in the last 3 months?
Does Savara offer dividend payments?
What is the current market capitalization of Savara?
When is the next SVRA earnings report date?

Savara Inc Company Profile

Savara Inc., positioned within the biomedical sphere, is a clinical-stage corporation directing its scientific pursuits towards mitigating the impacts of infrequent respiratory diseases. Chief among its therapeutic portfolio is molgramostim, an inhalable granulocyte-macrophage colony-stimulating factor, currently navigating its Phase 3 developmental journey. This pioneering medical compound exhibits significant promise in remedying autoimmune pulmonary alveolar proteinosis. Stationed in the historic Langhorne, Pennsylvania, Savara Inc.'s operations stimulate innovation and bring to light novel solutions for obscure respiratory conditions.

Sector:
Country:United States
Industry:
Address:1717 Langhorne Newtown Road, Suite 300, Langhorne
Employees:70
Website:savarapharma.com

Pros

Orphan drug market exclusivity period

High unmet medical need in rare disease

Specialized therapeutic area focus

Potential for global market expansion

Biologics manufacturing complexity as barrier

Cons

Single product candidate dependency

Inherent late-stage clinical trial risk

Pros

Cons

Company

AI Score

Compare

INVAInnoviva Inc

GOSSGossamer Bio Inc

PULMPulmatrix Inc

TBPHTheravance Biopharma Inc

MREOMereo BioPharma Group PLC

Company

AI Score

Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

SVRA Stock AI Analysis

Savara Inc

SVRA Stock AI Analysis

Savara Inc

SVRA AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

SVRA probability advantage of beating the market (3M): +3.08%

SVRA Trading Parameters

SVRA Proven Hold Signal & Price Forecast

SVRA Average Past Performance & Win Rate

SVRA Frequently Asked Questions

Will Savara stock go up?

What is the target price for Savara stock?

Is it a good time to buy, sell, or hold Savara stock right now?

Is Savara undervalued right now?

What was the price range of Savara stock over the past 12 months?

What is going on with Savara stock in the last 3 months?

Does Savara offer dividend payments?

What is the current market capitalization of Savara?

When is the next SVRA earnings report date?

Savara Inc Company Profile

Pros

Cons

Pros

Cons

SVRA Company Profile Summary

SVRA Related Investment Themes

SVRA Related Stocks

SVRA Top 10 Industry Stocks

Biotechnology

SVRA Top 10 Sector Stocks

Health Care

SVRA Stock AI Analysis

Savara Inc

NASDAQ NMS - GLOBAL MARKET

Will Savara stock go up?

What is the target price for Savara stock?

Is it a good time to buy, sell, or hold Savara stock right now?

Is Savara undervalued right now?

What was the price range of Savara stock over the past 12 months?

What is going on with Savara stock in the last 3 months?

Does Savara offer dividend payments?

What is the current market capitalization of Savara?

When is the next SVRA earnings report date?

Pros

Cons

NASDAQ NMS - GLOBAL MARKET

AI Score Explanation

SVRA Proven Hold Signal & Price Forecast